A translational grant from the Cancer Research Institute supporting bidirectional research that connects lab discoveries with clinical application in cancer immunology, including co-funded opportunities in chordoma with the Chordoma Foundation.
Eligibility Criteria:
-
Faculty appointment as tenure-track assistant professor (or higher) by award activation; if not yet appointed, institutional confirmation must accompany the LOI.
-
Research conducted at a non-profit medical school or research center in the United States or abroad.
-
No citizenship restrictions.
-
Not eligible: research at for-profit institutions.
Funding Details:
-
Total: USD 300,000 over 2 years (institution may take up to 10% indirects in addition to the award).
-
Competitive extension: additional USD 300,000 over 2 years (apply during Year 2 of the initial award based on exceptional progress).
-
Purpose: accelerate clinically relevant immunology (e.g., novel therapeutics, biomarkers, response prediction, resistance mechanisms, improved translational models).
-
Special opportunity: CRI–Chordoma Foundation co-funded projects; CF offers available models and banked tumor samples (including a 95-specimen TMA).
Deadline:
-
LOI deadline: December 1, 2025 (11:59 p.m. Eastern Time).
-
Invited full proposal deadline: March 2, 2026 (observed, as March 1 falls on a weekend).
-
Earliest start date: July 1 (awards activate on the first of the month).
Where to go for further information: